摘要
药品费用的急剧增长与医保基金有限承载能力之间的矛盾已经成为世界各国普遍面临的一大难题。我国台湾地区通过学习和探索,逐渐形成了一套较为完善的医保药品价格管理和支付制度,基本实现了从医院药品进价加成到药品支付价格基准分类定价及分组分类调整的跨越和逐步完善。其在药品医保定价、医保准入和价格调整上的独特政策制度设计可为我国大陆地区在医保控费背景下的医保药品管理改革和政策设计提供决策参考。
The contradiction between the rapid growth of drug costs and the limited carrying capacity of medical insurance funds has become a major problem in the world.Through study and exploration,Taiwan has gradually formed a set of relatively perfect medical insurance drug price management and payment system,basically realizing the leap and gradual improvement from the hospital drug price plus to the drug payment price benchmark classification pricing and grouping classification adjustment.The unique policy and system design on the pricing,access and price adjustment of medical insurance can provide decision-making reference for the reform and policy design of medical insurance drug management under the background of medical insurance fee control in China's Mainland.
作者
吕兰婷
傅金澜
Lyu Lanting;Fu Jinlan(School of Public Administration and Policy,Health Technology Assessment and Policy Evaluation Group of Renmin University of China,Beijing 100872,China)
出处
《中华医院管理杂志》
CSCD
北大核心
2020年第12期1011-1015,共5页
Chinese Journal of Hospital Administration
基金
中国人民大学科学研究基金(中央高校基本科研业务费专项资金资助)项目(20XNA004)。
关键词
药物经济学
社会保障
台湾地区
药品价格
医保支付
Pharmacoeconomics
Social security
Taiwan
Drug price
Medical insurance payment